Mounjaro® (Tirzepatide) is a revolutionary dual-action GIP/GLP-1 receptor agonist that optimizes glycemic control and weight management for Type 2 Diabetes (T2D). FDA-approved in 2022, it has shown remarkable efficacy in reducing HbA1c levels and body weight, surpassing GLP-1 therapies alone. The SURPASS-4 trial highlighted its additional benefit of lower mortality over insulin glargine, showcasing broader health potential. With a safety profile similar to GLP-1 agonists, Tirzepatide is poised to redefine T2D management and inspire further research into its effects on obesity and chronic diseases.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.
For detailed information about Trizapatide by Xeno Labs, consult with your doctor or healthcare professional.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Home
